GYRE
Price
$5.93
Change
-$0.20 (-3.26%)
Updated
Jul 28, 02:58 PM (EDT)
Capitalization
683.43M
21 days until earnings call
Intraday BUY SELL Signals
TIL
Price
$7.21
Change
+$0.07 (+0.98%)
Updated
Jul 28, 04:35 PM (EDT)
Capitalization
48.49M
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GYRE vs TIL

GYRE vs TIL Comparison Chart in %
View a ticker or compare two or three
VS
GYRE vs. TIL commentary
Jul 28, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and TIL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2026
Stock price -- (GYRE: $6.13 vs. TIL: $7.15)
Brand notoriety: GYRE and TIL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 27% vs. TIL: 58%
Market capitalization -- GYRE: $683.43M vs. TIL: $48.49M
GYRE [@Biotechnology] is valued at $683.43M. TIL’s [@Biotechnology] market capitalization is $48.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileTIL’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • TIL’s FA Score: 1 green, 4 red.
According to our system of comparison, both GYRE and TIL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 2 TA indicator(s) are bullish while TIL’s TA Score has 3 bullish TA indicator(s).

  • GYRE’s TA Score: 2 bullish, 7 bearish.
  • TIL’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, TIL is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а +4.25% price change this week, while TIL (@Biotechnology) price change was -1.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.93%. For the same industry, the average monthly price growth was -5.45%, and the average quarterly price growth was +2047.57%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 18, 2026.

TIL is expected to report earnings on Aug 07, 2026.

Industries' Descriptions

@Biotechnology (-4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($683M) has a higher market cap than TIL($48.5M). GYRE YTD gains are higher at: -13.173 vs. TIL (-35.000). GYRE has higher annual earnings (EBITDA): 5.07M vs. TIL (-67.54M). TIL has more cash in the bank: 79.7M vs. GYRE (49.8M). GYRE has less debt than TIL: GYRE (823K) vs TIL (84.9M). GYRE has higher revenues than TIL: GYRE (117M) vs TIL (0).
GYRETILGYRE / TIL
Capitalization683M48.5M1,408%
EBITDA5.07M-67.54M-8%
Gain YTD-13.173-35.00038%
P/E Ratio390.00N/A-
Revenue117M0-
Total Cash49.8M79.7M62%
Total Debt823K84.9M1%
FUNDAMENTALS RATINGS
GYRE vs TIL: Fundamental Ratings
GYRE
TIL
OUTLOOK RATING
1..100
8975
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
7575
P/E GROWTH RATING
1..100
8100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TIL's Valuation (7) in the Precious Metals industry is significantly better than the same rating for GYRE (98) in the null industry. This means that TIL’s stock grew significantly faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (95) in the null industry is in the same range as TIL (100) in the Precious Metals industry. This means that GYRE’s stock grew similarly to TIL’s over the last 12 months.

GYRE's SMR Rating (95) in the null industry is in the same range as TIL (99) in the Precious Metals industry. This means that GYRE’s stock grew similarly to TIL’s over the last 12 months.

GYRE's Price Growth Rating (75) in the null industry is in the same range as TIL (75) in the Precious Metals industry. This means that GYRE’s stock grew similarly to TIL’s over the last 12 months.

GYRE's P/E Growth Rating (8) in the null industry is significantly better than the same rating for TIL (100) in the Precious Metals industry. This means that GYRE’s stock grew significantly faster than TIL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYRETIL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signal:
Gain/Loss:
TIL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRSAX100.80N/A
N/A
T. Rowe Price Growth Stock Adv
MLPAX10.01N/A
N/A
Invesco SteelPath MLP Alpha A
CHRSX22.43N/A
N/A
Invesco Charter S
PIGDX4.32N/A
N/A
Federated Hermes International Growth IS
SBRVX18.24N/A
N/A
Segall Bryant & Hamill Sm Cp Val Ret